EUVIMEDEUVIMED entdecken
EditorialKommentar

Asymmetric Dimethylarginine in Pulmonary Arterial Hypertension

Thenappan Thenappan

JACC: Heart Failure · 2024

DOI: 10.1016/j.jchf.2024.04.015 ↗

Kurz gefasst

Editorial in der Zeitschrift JACC: Heart Failure, 2024. Verfasst von Thenappan Thenappan. Beteiligte Einrichtung: Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: tthenapp@umn.edu. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Arginine, Endothelium, Vascular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionArginineEndothelium, VascularHumansLiquid BiopsyBiomarkersFemaleMaleMiddle AgedPulmonary ArteryHypertension, Pulmonary

Stichwörter der Autor:innen

biomarkernitric oxidepulmonary hypertensionright ventricle

Substanzen

ArginineN,N-dimethylarginineBiomarkers

Autor:innen und Institutionen

  • Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: tthenapp@umn.edu.

Zitieren

APA

Thenappan, T. (2024). Asymmetric Dimethylarginine in Pulmonary Arterial Hypertension. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2024.04.015

Vancouver

Thenappan T. Asymmetric Dimethylarginine in Pulmonary Arterial Hypertension. JACC: Heart Failure. 2024. doi:10.1016/j.jchf.2024.04.015

BibTeX
@article{Thenappan2024,
  author = {Thenappan, Thenappan},
  title = {Asymmetric Dimethylarginine in Pulmonary Arterial Hypertension},
  journal = {JACC: Heart Failure},
  year = {2024},
  doi = {10.1016/j.jchf.2024.04.015}
}
Kostenlos starten →